158 related articles for article (PubMed ID: 19875393)
1. Bone health in HIV infection.
Pollock E; Klotsas AE; Compston J; Gkrania-Klotsas E
Br Med Bull; 2009; 92():123-33. PubMed ID: 19875393
[TBL] [Abstract][Full Text] [Related]
2. Bone changes and fracture risk in individuals infected with HIV.
Warriner AH; Mugavero MJ
Curr Rheumatol Rep; 2010 Jun; 12(3):163-9. PubMed ID: 20425517
[TBL] [Abstract][Full Text] [Related]
3. Interventions for the treatment of decreased bone mineral density associated with HIV infection.
Lin D; Rieder MJ
Cochrane Database Syst Rev; 2007 Apr; (2):CD005645. PubMed ID: 17443607
[TBL] [Abstract][Full Text] [Related]
4. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for low bone mineral density in HIV-infected subjects.
Cotter AG; Mallon PW
Curr HIV/AIDS Rep; 2012 Jun; 9(2):148-59. PubMed ID: 22528765
[TBL] [Abstract][Full Text] [Related]
6. Management of bone mineral density in HIV-infected patients.
Negredo E; Bonjoch A; Clotet B
Expert Opin Pharmacother; 2016; 17(6):845-52. PubMed ID: 26809940
[TBL] [Abstract][Full Text] [Related]
7. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
[TBL] [Abstract][Full Text] [Related]
8. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
Huang J; Meixner L; Fernandez S; McCutchan JA
AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
[TBL] [Abstract][Full Text] [Related]
9. Bone disorders in human immunodeficiency virus infection.
Glesby MJ
Clin Infect Dis; 2003; 37 Suppl 2():S91-5. PubMed ID: 12942380
[TBL] [Abstract][Full Text] [Related]
10. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies.
Walker Harris V; Brown TT
J Infect Dis; 2012 Jun; 205 Suppl 3(Suppl 3):S391-8. PubMed ID: 22577213
[TBL] [Abstract][Full Text] [Related]
11. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
[TBL] [Abstract][Full Text] [Related]
12. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
13. HIV infection and bone disease.
Compston J
J Intern Med; 2016 Oct; 280(4):350-8. PubMed ID: 27272530
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density loss, osteoporosis, and fractures in HIV.
Labarga P
AIDS Rev; 2013; 15(3):189-90. PubMed ID: 24002203
[TBL] [Abstract][Full Text] [Related]
15. HIV infection and bone disease: implications for an aging population.
Cotter AG; Mallon PW
Sex Health; 2011 Dec; 8(4):493-501. PubMed ID: 22127034
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy.
Bunders MJ; Frinking O; Scherpbier HJ; van Arnhem LA; van Eck-Smit BL; Kuijpers TW; Zwinderman AH; Reiss P; Pajkrt D
Clin Infect Dis; 2013 Feb; 56(4):583-6. PubMed ID: 23097583
[TBL] [Abstract][Full Text] [Related]
18. Bone disease in the setting of HIV infection: update and review of the literature.
Castronuovo D; Cacopardo B; Pinzone MR; Di Rosa M; Martellotta F; Schioppa O; Moreno S; Nunnari G
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(18):2413-9. PubMed ID: 24089217
[TBL] [Abstract][Full Text] [Related]
19. A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.
Ofotokun I; Titanji K; Lahiri CD; Vunnava A; Foster A; Sanford SE; Sheth AN; Lennox JL; Knezevic A; Ward L; Easley KA; Powers P; Weitzmann MN
Clin Infect Dis; 2016 Sep; 63(5):663-671. PubMed ID: 27193748
[TBL] [Abstract][Full Text] [Related]
20. Stable bone density in HAART-treated individuals with HIV: a meta-analysis.
Bolland MJ; Wang TK; Grey A; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2011 Sep; 96(9):2721-31. PubMed ID: 21715534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
